Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions

The CDC Advisory Committee on Immunization Practices (ACIP) recommended immunization with the recently licensed 13-valent pneumococcal conjugate vaccine (PCV13) for high-risk (immunocompromised) adults aged ≥19 years in 2012. This was in addition to the 23-valent pneumococcal polysaccharide vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Vietri, Jeffrey, Harnett, James, Emir, Birol, Chilson, Erica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012081/
https://www.ncbi.nlm.nih.gov/pubmed/31343949
http://dx.doi.org/10.1080/21645515.2019.1632683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012081/
https://www.ncbi.nlm.nih.gov/pubmed/31343949
http://dx.doi.org/10.1080/21645515.2019.1632683

Ejemplares similares